Evidence map›Paper›PMID 27142677›Full record

ArticleEuropean journal of human genetics : EJHG2016

Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland.

Luca Trotta, Timo Hautala, Sari Hämäläinen, Jaana Syrjänen, Hanna Viskari, Henrikki Almusa, Maija Lepisto, Meri Kaustio, Kimmo Porkka, Aarno Palotie and 2 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Insights on SNPs of Human Activation-Induced Cytidine Deaminase AID.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Luca TrottaInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Timo HautalaDepartment of Internal Medicine, Oulu University Hospital, Oulu, Finland.
Sari HämäläinenDepartment of Internal Medicine, Kuopio University Hospital, Kuopio, Finland.
Jaana SyrjänenDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Hanna ViskariDepartment of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Henrikki AlmusaInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Maija LepistoInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Meri KaustioInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Kimmo PorkkaHematology Research Unit, Biomedicum Helsinki and Hematology Division, Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Aarno PalotieInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Mikko SeppänenRare Disease Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Janna SaarelaInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIInstitute for Molecular Medicine Finland · FIFinland University · FIHelsinki University Hospital · FIKuopio University Hospital · FIOulu University Hospital · FITampere University · FITampere University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody class-switch recombination and somatic hypermutation critically depend on the function of activation-induced cytidine deaminase (AID). Rare variants in its gene AICDA have been reported to cause autosomal recessive AID deficiency (autosomal recessive hyper-IgM syndrome type 2 (HIGM2)). Exome sequencing of a multicase Finnish family with an HIGM2 phenotype identified a rare, homozygous, variant (c.416T>C, p.(Met139Thr)) in the AICDA gene, found to be significantly enriched in the Finnish population compared with other populations of European origin (38.56-fold, P<0.001). The population history of Finland, characterized by a restricted number of founders, isolation and several population bottlenecks, has caused enrichment of certain rare disease-causing variants and losses of others, as part of a phenomenon called the Finnish Disease Heritage. Accordingly, rare founder mutations cause the majority of observed Finnish cases in these mostly autosomal recessive disorders that consequently are more frequent in Finland than elsewhere. Screening of all currently known Finnish patients with an HIGM2 phenotype showed them to be homozygous for p.(Met139Thr). All the Finnish p.(Met139Thr) carriers with available data on their geographic descent originated from the eastern and northeastern parts of Finland. They were observed to share more of their genome identity by descent (IBD) than Finns in general (P<0.001), and they all carried a 207.5-kb ancestral haplotype containing the variant. In conclusion, the identified p.(Met139Thr) variant is significantly enriched in Finns and explains all thus far found AID deficiencies in Finland.

Indexed as

Gene FrequencyMutationPedigreeAdultAICDA (Activation-Induced Cytidine Deaminase)ChildCytidine DeaminaseFemaleFinlandFounder EffectHaplotypesHeterozygoteHomozygoteHumansHyper-IgM Immunodeficiency SyndromeInfantAICDA (Activation-Induced Cytidine Deaminase)Cytidine Deaminase

Identifiers

PMID27142677
PMCPMC5027683
OpenAlexW2345671041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.